VectivBio Holding AG (NASDAQ:VECT – Get Rating) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 56,700 shares, a drop of 59.6% from the February 13th total of 140,500 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 17,600 shares, the days-to-cover ratio is presently 3.2 days.
VectivBio Price Performance
VectivBio stock traded down $0.08 during mid-day trading on Friday, hitting $8.22. The stock had a trading volume of 5,303 shares, compared to its average volume of 22,046. The stock has a 50-day simple moving average of $8.26 and a two-hundred day simple moving average of $7.51. VectivBio has a 12 month low of $3.81 and a 12 month high of $9.45.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group initiated coverage on VectivBio in a research note on Tuesday, December 13th. They issued a “buy” rating and a $18.00 target price for the company.
Hedge Funds Weigh In On VectivBio
Several hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC boosted its holdings in VectivBio by 15.4% in the second quarter. Citadel Advisors LLC now owns 3,143,237 shares of the company’s stock valued at $16,973,000 after acquiring an additional 420,591 shares during the last quarter. Vivo Capital LLC bought a new position in VectivBio during the fourth quarter worth about $20,218,000. VR Adviser LLC bought a new position in VectivBio during the fourth quarter worth about $16,169,000. Driehaus Capital Management LLC boosted its holdings in VectivBio by 100.8% during the fourth quarter. Driehaus Capital Management LLC now owns 1,716,656 shares of the company’s stock worth $14,780,000 after buying an additional 861,921 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in VectivBio by 172.5% during the fourth quarter. Marshall Wace LLP now owns 1,369,656 shares of the company’s stock worth $11,793,000 after buying an additional 867,000 shares during the last quarter. Institutional investors own 90.52% of the company’s stock.
VectivBio Company Profile
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy.